Syndax Pharmaceuticals (NASDAQ:SNDX) versus Insmed (NASDAQ:INSM) Critical Review

by · The Cerbat Gem

Insmed (NASDAQ:INSM – Get Free Report) and Syndax Pharmaceuticals (NASDAQ:SNDX – Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, analyst recommendations, profitability, risk and earnings.

Profitability

This table compares Insmed and Syndax Pharmaceuticals’ net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Insmed-39.85%-96.38%-32.55%
Syndax Pharmaceuticals-72.32%-804.38%-34.93%

Valuation and Earnings

This table compares Insmed and Syndax Pharmaceuticals”s gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Insmed$606.42 million44.45-$1.28 billion($2.82)-43.57
Syndax Pharmaceuticals$172.35 million4.77-$285.42 million($2.36)-3.87

Syndax Pharmaceuticals has lower revenue, but higher earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Syndax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Insmed has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500. Comparatively, Syndax Pharmaceuticals has a beta of 0.48, meaning that its stock price is 52% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and target prices for Insmed and Syndax Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Insmed112312.92
Syndax Pharmaceuticals101002.82

Insmed presently has a consensus target price of $196.52, suggesting a potential upside of 59.93%. Syndax Pharmaceuticals has a consensus target price of $41.60, suggesting a potential upside of 355.64%. Given Syndax Pharmaceuticals’ higher possible upside, analysts clearly believe Syndax Pharmaceuticals is more favorable than Insmed.

Summary

Insmed beats Syndax Pharmaceuticals on 9 of the 12 factors compared between the two stocks.

About Insmed

(Get Free Report)

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing treatments for serious diseases, including respiratory and rare conditions. The company is based in Bridgewater, New Jersey, and is led by President and Chief Executive Officer William H. Lewis Jr. Its commercial products include ARIKAYCE, an inhaled amikacin treatment for certain adults with refractory Mycobacterium avium complex lung disease, and BRINSUPRI (brensocatib), an oral treatment for non-cystic fibrosis bronchiectasis.

About Syndax Pharmaceuticals

(Get Free Report)

Syndax Pharmaceuticals is a biotechnology company focused on developing and commercializing medicines for cancer and related serious diseases. Its research programs include therapies that target cancer-driving pathways, including menin and the colony-stimulating factor 1 receptor (CSF-1R). The company’s medicines include Revuforj (revumenib), approved in the United States for certain adults and children aged one year and older with relapsed or refractory acute leukemia involving a KMT2A translocation.